Abstract
severe infections with multiresistant bacteria (MRB) are a medical challenge and a financial burden for hospitals. the adequate antibiotic therapy is a key issue in multiresistant bacteria management. several major cost drivers have been identified. Remarkably drug acquisition costs are not necessarily included. Most significant are the length of stay in hospital, the hours of mechanical ventilation and the time treated on an intensive care unit.
In a systematic review of the literature the following aspects were investigated: -do generic treatment strategies contribute in cost savings? -are there specific results for recent antibiotics?
Early adequate and effective antimicrobial treatment, switch from i.v. to oral therapy, adjusted duration of therapy and adherence to guidelines have been found to be successful strategies.
looking at specific antibiotics, the best evidence for cost-effectiveness is found for linezolid in treatment of csstI as well as in HaP. daptomycin shows good economic results in bloodstream infections, so possibly being a cost-effective alternative to vancomycin. looking at tigecycline the published data show neither higher costs nor savings compared to imipeneme. doripenem as one of the newest therapy options has proven to be highly cost-saving in HaP when compared with imipenem. However, most analyses are based on pharmacoeconomic modelling rather than on directly analysing trial data or real life clinical populations. Conclusion: using modern antibiotics in whole is not more expensive than using established therapies. Modern antibiotics are cost-effective and sometimes even cost-saving. this is especially true if an effective therapy is initiated as early as possible.
abbreviations: alos = average length of stay in a given dRG, basis for determining whether a patient causes more costs than reimbursement caP = community acquired pneumonia csstI = complicated skin and soft tissue infections dRG = diagnoses related groups, systems to classify patients based on their resource consumptions HaP = hospital acquired pneumonia HMV = hours of mechanical ventilation Icu-days = treatment days on an intensive care unit los = length of stay in hospital MRB = infection with Multiresistant bacteria IntRoductIon severe MRB cause a serious burden of disease in most countries worldwide [1, 2, 6, 23] . their therapeutic management is a major cost driver in healthcare , particularly in hospitals. looking at the economical impact of antibiotic therapy of severe MRB infections, several factors were identified as the major cost drivers Whether any given antibiotic therapy is an economically adequate option therefore depends on its effect on one or more of these cost drivers. Interestingly, the actual daily costs of the drug itself does not significantly affect the overall costs of treatment. still in many settings, the choice of therapy is controlled by drug acquisition costs, as these data are easily available [7, 8] .
this article provides a review of the current literature on the role of recent antibiotic agents in the treatment of MRB infections from the economical perspective.
MatERIals and MEtHods
We conducted a literature review to investigate the available evidence on cost-effectiveness of antibiotic treatment strategies in the management of MRB infections. looking at the economical impact of antibiotic therapy in general, there are the following factors that have been proven to influence positively the abovementioned cost drivers: Influencing factor Effect on cost driver Ref.
Early adequate first-line antibiotic therapy shorter duration of therapy Early transfer from Icu to normal ward shorter los less complications [9] [10] [11] [12] [13] IV-to-oral switch shorter i.v. therapy Earlier discharge and outpatient treatment [14] [15] [16] [17] adjusted duration of therapy less adverse events less selection of resistance less drug cost shorter los [18] [19] [20] [21] [22] adherence to guidelines shorter duration of therapy shorter los less complications less Icu admissions less HMV [7, 24, 25] With respect to these known factors affecting major cost drivers, we conducted a literature review focussed on articles dealing with recently introduced antibiotics active against MRB in the context of cost issues or cost-impacting factors.
We used the agent and 'cost-effectiveness' oR 'economical' as search terms.
REsults
We had 178 search findings in total. figure 1 shows the search findings.
the number of publications referring explicitely to cost-effectiveness or economical analyses on linezolid is the highest. for closer analysis we then picked 25 articles that focussed on one or more of our above mentioned cost drivers.
In general economical analyses for drugs often differ from clinical trials. the most common method is modelling economical effects by using results from clinical trials. only rarely economical data are directly collected in the course of clinical trials. nearly no data exist on economical analyses based on clinical routine treatment. figure 2 shows the results of the 25 articles closely reviewed.
In the following section we describe major findings for the agents in focus.
lInEzolId Multiple economic analyses for linezolid have been published over the last decade. there are publications for both major indications (csstI, HaP) and for several countries (usa, Germany, spain, france). thus the economics of linezolid use effects appear to be well investigated. studies are either cost-effectiveness analyses based on data of clinical trials or pharmacoeconomic models [26] [27] [28] [29] [30] . the cost savings associated with the use of linezolid are predominantly due to a significant reduction of los. among recent antibiotics used for MRB infection, linezolid is the only drug that is available intravenous (IV) and orally (with a similar dose/exposure ratio), and the IV-to-oral switch allows earlier hospital discharge. the net effect is most significant in the treatment of csstI (2.0 -2.3 los days saved), as the overall severity of illness is lower than in pneumonia, and hospital-acquired pneumonia in particular. However, linezolid has been shown to be cost-effective in pneumonia as well. this is most likely due to earlier recovery and earlier hospital discharge. Most authors today acknowledge linezolid as a cost-effective component of the therapeutic armamentarium, particularly in MRsa infections [32] . However, this insight has not been entirely implemented in clinical practice yet [33] .
there are no explicit analyses available for other cost drivers. Most recently, a meta-analysis [31] suggested that there is no specific economic rationale supporting the use of vancomycin versus linezolid for empiric therapy in settings with low MRsa prevalence. daPtoMycIn Introduced more recently than linezolid, daptomycin already prompted a substantial number of publications on economic issues and publications referring to significant cost drivers [34] [35] [36] [37] [38] [39] [40] . the most relevant indication for daptomycin is bloodstream infection with gram-positive cocci, as the overall number of patients is significantly higher than in endocarditis. similar to most of the other drugs discussed here, daptomycin is also suitable for the treatment of csstI. the main economic impact of daptomycin is associated with a reduction of los. However, earlier transfer from Icu to general ward is also described. some publications [35, [37] [38] [39] attribute lower costs to earlier cure and higher cure rates achieved with daptomycin versus vancomycin, which may relate to the bactericidal effect of the drug. However the trials underlying these analyses were no Rcts.
daptomycin has been shown to be associated with less occurrence of renal failure than vancomycin [34] . It thus may be speculated that the lipopeptide antibiotic has a potential to influence positively the cost-driving duration of therapy as mentioned in one publication (39) . However, this aspect still awaits further investigation. doRIPEnEM convincing economic analyses and articles referring to cost drivers in clinical studies have been published for doripenem, a recently approved carbapenem antibiotic [41] [42] [43] [44] [45] . doripenem was shown to be associated with less resource use regarding los, HMV, and less complications (Psa resistance, Psa transmissions) compared to imipenem. no significant reduction in Icu days has been described so far. Remarkably, economical evaluation of this drug was included in the data and analysis of clinical trials. tIGEcyclInE among the articles retrieved on tigecycline [46] [47] [48] [49] [50] [51] , there were two dedicated analyses that dealt with resource utilization (i.e. cost) associated with the use of this recently introduced glycylcyclin antibiotic [49] . tigecycline is an interesting treatment option particularly in complicated intraabdominal infections. With its very broad spectrum of activity, tigecycline can be used empirically in suspected polymicrobial infections. despite the slightly higher drug acquisition costs compared to imipenem it has been showed that first-line therapy is not more expensive than using tigecycline in second-line therapy [51] . It also has the potential to be used as a monotherapy in this indication [48] and therefore would affect overall costs by abolishing the need for another drug. two publications explicitly report that los was not negatively affected when comparing tigecycline with imipenem [49, 50] . It appears that the number of publications that evaluate the economic impact of new antimicrobial agents such as linezolid, daptomycin, tigecycline and doripenem is increasing. for every substance there are results or at least trends that indicate favourable effects on economic outcomes. the studies uniformly show that despite higher drug acquisition costs for newer antibiotics, overall treatment costs can be lower or therapy is cost-effective due to other factors (i.e. survival for linezolid in pneumonia). only a limited number of studies analyzed ‚real-life' clinical populations [11-13, 24, 27, 28, 37, 39] , whereas the greater part of the publications used pharmacoeconomic models based on data from clinical trials. While this is a well-accepted approach, it does not prove the relevance of the respective findings in the clinical routine setting. obviously, it is a most challenging task to validate data from pharmacoeconomic models in "real life", as the variance of patient characteristics is much higher than in trial population and various confounders complicate such analyses. there are some ongoing studies trying to relate dRG outcomes -i.e. the net effect on hospital reimbursement -to the chosen therapy strategies. It will be interesting to see the results in the near future. conclusIon the economic impact of antibiotic treatment choices in complicated infections with multiresistant bacteria is an increasingly important issue, as numerous publications document the enormous extra healthcare cost of these infections (1, 3, 4, 9, 10, 13, 36, 41) . the analysis of the current literature shows that therapy with modern antibiotics is generally cost-effective and may even be associated with net savings although drug acquisition costs are higher in conventional therapy regimens. currently, favourable cost effects are best documented for linezolid. a number of pharmacoeconomic analyses are also available for daptomycin, tigecyclin and doripenem, and more will certainly follow. Investigators may increasingly use economic data to document favourable cost effects of state-of-the-art therapy, thus overcoming the still wide-spread focus on ‚price-tags'. However only a few analyses use 'reallife' clinical settings for cost analyses. Modelling is the most common and most accepted approach to gain 'economical evidence'. With directly connecting economical analyses to clinical trials and/or to routine data collections the results would reach a higher level of acceptance among hospital administrators.
clinicians, pharmacists and economists in the hospital should work together to realize cost-savings with effective antibiotic therapy rather than sticking to treatment choices driven by drug acquisition cost.
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